Your session is about to expire
← Back to Search
AXS-12 for Narcolepsy
Study Summary
This trial will study how effective and safe AXS-12 is for people with narcolepsy, specifically those with cataplexy and excessive daytime sleepiness.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
- Group 1: Placebo
- Group 2: AXS-12 (reboxetine)
Frequently Asked Questions
Who does this study hope to include in its research?
"Up to 90 narcolepsy patients aged 15-75 can participate in this study, pending they are able and willing to follow the study's guidelines."
If I am older than 45, can I still participate in this clinical research?
"According to the rules that define who can participate in this research, the youngest person that can enroll is 15 years old and the oldest is 75."
Are there previous examples of AXS-12's (reboxetine) efficacy?
"AXS-12 (reboxetine) was first introduced in 2008 through clinical trials at Parc Sanitari Sant Joan de Déu. Since then, a total of 18,271 trials have been completed. Currently, there are 5 trials recruiting patients with a significant portion based in Charleston, South carolina."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
What site did they apply to?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger